Verona Pharma plc
VRNA
Rang în acțiuni
#2230
Verona Pharma plc is a biopharmaceutical company currently in its clinical... Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.
Preț acțiune
$106.91
Ultima sincronizare: 2025-10-07
Capitalizare de piață
$9.09B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
0.00%
Țară
GB
Tranzacționează Verona Pharma plc (VRNA)
Categorie
Healthcare
Venituri pentru Verona Pharma plc (VRNA)
Venituri în Jun 2025 TTM: $167.65M
Conform celor mai recente rapoarte financiare ale Verona Pharma plc, venitul actual al companiei (TTM) este $167.65M. În anul 2023, compania a avut un venit de 0.00 o scădere comparativ cu venitul din anul 2022, care a fost de $378.87K. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru Verona Pharma plc din 2005 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $167.65M | 396.46% |
| 2024 | $33.77M | 0.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $378.87K | -98.72% |
| 2021 | $29.58M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 7,429.97% |
US
|
|
| $2.23B | 1,228.93% |
US
|
|
| $15.74B | 9,290.96% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 3,491.50% |
NL
|
